476475-44-2 Usage
Description
6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-Methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, Methyl ester is a methyl ester derivative of 6-quinolinecarboxylic acid, featuring a pyrrolopyrazole group and a methyl-2-pyridinyl group. It is a heterocyclic compound with potential applications in pharmaceutical research and drug development due to its unique structural features and potential biological activity.
Used in Pharmaceutical Research:
6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-Methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, Methyl ester is used as a research compound for exploring its potential biological activity and therapeutic properties.
Used in Drug Development:
6-Quinolinecarboxylic acid, 4-[5,6-dihydro-2-(6-Methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-, Methyl ester is used as a starting material or intermediate in the synthesis of new drugs, particularly those targeting various diseases and conditions.
Further research is needed to fully understand the properties and potential uses of this chemical compound in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 476475-44-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,6,4,7 and 5 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 476475-44:
(8*4)+(7*7)+(6*6)+(5*4)+(4*7)+(3*5)+(2*4)+(1*4)=192
192 % 10 = 2
So 476475-44-2 is a valid CAS Registry Number.
476475-44-2Relevant articles and documents
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-β type I receptor kinase domain inhibitors: Discovery of an orally bioavailable transforming growth factor-β receptor type I inhibitor as antitumor agent
Li, Hong-Yu,McMillen, William T.,Heap, Charles R.,McCann, Denis J.,Yan, Lei,Campbell, Robert M.,Mundla, Sreenivasa R.,King, Chi-Hsin R.,Dierks, Elizabeth A.,Anderson, Bryan D.,Britt, Karen S.,Huss, Karen L.,Voss, Matthew D.,Wang, Yan,Clawson, David K.,Yingling, Jonathan M.,Sawyer, J. Scott
, p. 2302 - 2306 (2008/12/20)
In our continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, we have discovered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor 15d (LY2109761) is representative of a novel series of antitumor agents.
